Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
AGs Identified for 4 Brands in Latest Generic Approvals, Including Bonviva and Epadel
At least four authorized generics (AGs) have emerged from the Ministry of Health, Labor and Welfare’s latest batch of approvals granted on August 15, Jiho has learned. Among them, two represent so-called “follow-on AGs,” which arrive after standard generics have…
To read the full story
Related Article
- Nipro to List Forxiga AG in June Ahead of Pricing Rule Shift
April 30, 2026
- Mochida Releases Authorized Generic of Epadel S in Japan
December 8, 2025
- Vimpat Draws 10 Generic Entrants in December Listing; Forxiga Has Two, but Nipro AG Absent
December 4, 2025
- Nipro Secures AG for Forxiga, Sawai and Teva Takeda Go Without Hydrate
August 18, 2025
- Japan Approves First SGLT2 Generics, 12 Firms Pile into Vimpat Ahead of December Listing
August 18, 2025
BUSINESS
- Toho Subsidiary Suffers Data Breach, HCP Info Exposed
October 20, 2026
- Veritas, Toray Pin Down Hit Compounds for PCSK9 mRNA Drugs
October 20, 2026
- Insmed’s Brinsupri Hits Japan Market for NCFB
October 20, 2026
- Ex-Alfresa Chairman Arata Watanabe Dies at 85
October 20, 2026
- TS Alfresa-Backed Drone Council Inks Pact with Hiroshima
October 19, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…